Success Metrics

Clinical Success Rate

100.0%

Based on 8 completed trials

Completion Rate

100%(8/8)

Active Trials

0(0%)

Results Posted

88%(7 trials)

Phase Distribution

Ph phase_3

25%

Ph phase_2

38%

Ph phase_4

13%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (25.0%)

Phase 23 (37.5%)

Phase 32 (25.0%)

Phase 41 (12.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_3

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

NCT01491607

completedphase_1

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT03877926Phase 3

VELOCITY: An Anthrax Vaccine Clinical Study

Completed

NCT03352466Phase 1

NasoShield Study of Safety and Immunogenicity

Completed

NCT01753115Phase 2

Ciprofloxacin BioThrax Co-Administration Study

Completed

NCT01491607Phase 3

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

Completed

NCT01263691Phase 1

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

Completed

NCT01770743Phase 2

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

Completed

NCT03518125Phase 2

BARDA Securing Anthrax Immunity For the Elderly

Completed

NCT01641991Phase 4

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

Completed

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8